In a groundbreaking advancement that could redefine the therapeutic landscape of prostate cancer, a team of researchers has unveiled a novel molecular mechanism by which prostate cancer metastasizes. The study, led by Liu, Guo, You, and their colleagues, illuminates the pivotal role of RBM14, an RNA-binding protein, in facilitating the aggressive spread of prostate cancer cells. This mechanism operates through the stabilization of HK2 mRNA, catalyzing a metabolic shift that not only ramps up glycolysis but also induces a unique epigenetic modification known as H3K18 lactylation. Published in Cell Death Discovery in 2026, these findings shed light on the intricate interplay between metabolism and epigenetic regulation in cancer progression, offering promising new targets for intervention.
Prostate cancer metastasis remains one of the greatest clinical challenges, significantly escalating mortality associated with this common malignancy. While previous research has extensively investigated genetic mutations and signaling pathways driving cancer spread, this study introduces a fresh perspective by linking metabolic regulation and epigenetic modifications to metastatic behavior. RBM14, traditionally recognized for its role in RNA metabolism, has now emerged as a critical mediator stabilizing HK2 mRNA, thereby sustaining elevated glycolytic activity. This metabolic reprogramming provides metastatic cancer cells with a rapid energy supply and biosynthetic precursors essential for invasion and survival in distant tissues.
The molecular architecture of this pathway reveals that RBM14 binds directly to HK2 mRNA, protecting it from degradation. Hexokinase 2 (HK2) is a key enzyme catalyzing the initial step of glycolysis by phosphorylating glucose to glucose-6-phosphate, effectively committing glucose to cellular energy metabolism. Enhanced HK2 expression driven by RBM14 ensures an abundant flux through glycolysis, a hallmark of aggressive cancer metabolism often termed the “Warburg effect”. However, the authors uniquely emphasize that this metabolic shift is not merely a consequence but an active driver of metastatic progression thanks to its downstream effects on chromatin modifications.
Intriguingly, the robust glycolytic activity fueled by RBM14-mediated HK2 stabilization leads to elevated intracellular lactate levels. Lactate, traditionally regarded as a metabolic byproduct, has recently been recognized for its signaling functions and involvement in epigenetic regulation. The study highlights H3K18 lactylation, a histone modification where lactate moieties are appended to lysine 18 on histone H3, as a direct epigenetic mark induced by this metabolic rewiring. This histone lactylation event significantly reprograms gene expression profiles to favor metastatic phenotypes, including enhanced motility, invasiveness, and resistance to apoptosis.
From a biochemical perspective, this research integrates the fields of RNA biology, metabolism, and epigenetics into a comprehensive framework explaining prostate cancer metastasis. The use of advanced RNA immunoprecipitation and next-generation sequencing analyses validated the binding affinity of RBM14 for HK2 transcripts and demonstrated the consequent augmentation in glycolytic gene networks. Furthermore, chromatin immunoprecipitation coupled with mass spectrometry provided compelling evidence for the presence and functional significance of H3K18 lactylation in tumor samples exhibiting high RBM14 expression.
In vitro and in vivo experiments further consolidated the conceptual model, where knockdown of RBM14 led to the destabilization of HK2 mRNA, a marked decrease in glycolysis rates, and subsequent reduction in H3K18 lactylation. This intervention translated into diminished metastatic potential in prostate cancer cell lines and mouse xenograft models, underscoring the therapeutic promise of targeting RBM14 or its downstream metabolic and epigenetic pathways. Notably, the study also explored small molecule inhibitors capable of disrupting the RBM14-HK2 interaction, revealing preliminary efficacy in curtailing metastatic spread.
This body of work not only highlights RBM14 as a molecular linchpin in prostate cancer metastasis but also challenges the traditional compartmentalization of metabolic and epigenetic regulation as independent axes of cancer biology. The interplay elucidated here points to a highly integrated regulatory network, suggesting that cancer cells exploit metabolic intermediates not solely for energy but as epigenetic modulators to tightly control gene expression in favor of malignancy. Moreover, lactylation emerges as a key epigenetic marker with potential diagnostic and prognostic implications within the prostate cancer continuum.
The clinical implications beckon a new era of metabolic and epigenetic targeted therapy. Given the poor prognosis associated with metastatic prostate cancer, strategies inhibiting RBM14-mediated HK2 mRNA stabilization or disrupting lactate-driven histone modifications could provide transformative benefits. Early-phase clinical trials targeting similar metabolic pathways in other cancers lend credence to the translational feasibility of this approach. Future research might focus on pharmacologic agents specifically designed to modulate lactylation or RBM14 activity, potentially revolutionizing treatment paradigms for metastatic prostate cancer.
Beyond prostate cancer, these findings may have broader impact across oncology, as metabolic-epigenetic cross-talk likely underlies metastatic behaviors in diverse tumor types. RBM14’s role as an RNA-binding protein stabilizer could be a general mechanism leveraged by cancer cells to sustain metabolic adaptations critical for dissemination. The identification of lactylation opens avenues for discovering other lactate-dependent epigenetic marks influencing chromatin state and cancer evolution. This work thus provides a conceptual template for exploring metabolic regulation of chromatin in cancer progression.
Scientifically, the revelation of H3K18 lactylation as a pro-metastatic epigenetic modification invites deeper inquiries into the enzymatic machinery responsible for adding and removing these lactyl groups. Decoding the “writers,” “readers,” and “erasers” of histone lactylation will enrich understanding of how metabolic flux integrates with gene regulation and how such mechanisms are exploited in cancer. Additionally, the crosstalk between lactylation and other histone marks, such as acetylation and methylation, may reveal complex layers of epigenetic control fine-tuning cancer cell identity and plasticity.
On a methodological note, this study exemplifies the power of combining multi-omics approaches, including transcriptomics, metabolomics, and epigenomics, to untangle the multidimensional regulatory networks driving cancer aggressiveness. The sophisticated experimental design involving genetic, biochemical, and pharmacological manipulations allowed for a nuanced dissection of cause-and-effect relationships in the RBM14-HK2-lactylation axis. This comprehensive approach sets a new standard for dissecting molecular pathways underpinning metastasis and highlights the importance of interdisciplinary collaboration.
In sum, Liu, Guo, You, and colleagues’ discovery of RBM14’s role in stabilizing HK2 mRNA to activate glycolysis and induce H3K18 histone lactylation unveils a vital metabolic-epigenetic circuit fueling prostate cancer metastasis. This landmark study not only advances fundamental understanding of cancer biology but also identifies promising therapeutic targets to impede the spread of a devastating disease. As the oncology community seeks innovative strategies to combat metastasis, targeting the metabolic-epigenetic interface illuminated here represents a compelling frontier with enormous translational potential.
The emerging paradigm underscored by this research suggests that future oncologic therapies may need to simultaneously address metabolic vulnerabilities and epigenetic dynamics to effectively halt the complex process of metastasis. By illuminating how RBM14 orchestrates glycolysis and epigenetic remodeling through HK2 mRNA stabilization and H3K18 lactylation, the study paves the way for novel biomarkers and combinatorial treatment strategies aiming at metabolic and epigenetic aberrations. This comprehensive insight fosters hope for markedly improved outcomes for patients suffering from advanced prostate cancer.
In conclusion, this study fundamentally reshapes the understanding of how metabolic reprogramming and histone modifications intersect to drive prostate cancer metastasis. The identification of RBM14 as a critical stabilizer of HK2 mRNA and the elucidation of H3K18 lactylation as a pivotal epigenetic modification open profound new vistas for cancer research and therapeutics. As we advance toward precision medicine, integrating metabolic and epigenetic targeting holds the promise of unlocking more effective therapies to arrest cancer progression and improve patient survival.
Subject of Research: Role of RBM14 in prostate cancer metastasis via HK2 mRNA stabilization and activation of glycolysis and epigenetic modification (H3K18 lactylation).
Article Title: RBM14 drives prostate cancer metastasis via stabilizing HK2 mRNA to activate glycolysis and H3K18 lactylation.
Article References: Liu, Z., Guo, H., You, Z. et al. RBM14 drives prostate cancer metastasis via stabilizing HK2 mRNA to activate glycolysis and H3K18 lactylation. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-03131-w
Image Credits: AI Generated
DOI: https://doi.org/10.1038/s41420-026-03131-w
